The University of Kansas Cancer Center (KUCC) is a matrix cancer center that includes: the University of Kansas Medical Center campuses in Kansas City and Wichita, the University of Kansas-Lawrence, and the Stowers Institute for Medical Research (via consortium agreement). In 2010, 143 members of KUCC accounted for $11.4 million of NCI funding and a total of $55.1 million in overall cancer-related funding. KUCC is led by Roy A. Jensen, M.D. who is supported by a strong, nationally recognized leadership team. Over the last seven years substantial progress has been made securing institutional commitment, recruiting key leadership positions, building nationally significant research programs, developing our clinical research program, improving and expanding our facilities, and creating transdisciplinary and collaborative interactions. With input from our External Advisory Board, we have established three goals for KUCC that will insure we make a national impact in the fight against cancer: Goal 1: Become the leading academic institution for transforming discoveries from the laboratory into new anticancer drug therapies. Goal 2: Provide the optimal environment for basic, translational, clinical, and population-based research in oncology by developing and fostering a collaborative, collegial, and dynamic culture of scientific inquiry. Goal 3: Be a nationally recognized leader in partnering with community oncologists and other key stakeholders to develop, promote, and foster the adoption and implementation of research-based cancer prevention, diagnosis, treatment, control, and survivorship practices throughout our service area. To accomplish these goals KUCC has four research programs including: Cancer Biology, Cancer Control and Population Health, Cancer Prevention, and Drug Discovery, Delivery and Experimental Therapeutics. In addition, the Cancer Center supports four shared resources: Biostatistics and Informatics, Lead Development and Optimization, Biospecimen, and Clinical Trials Management.

Public Health Relevance

KUCC aims to leverage unique regional scientific assets to build a nationally significant cancer research center that will become a leading institution for transforming discoveries in the laboratory into new therapeutic approaches. We hope to establish an NCI-designated cancer center to meet the needs of the more than five million Americans who live within the 120,000 square miles of our catchment area.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Shafik, Hasnaa
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Kansas
Schools of Medicine
Kansas City
United States
Zip Code
Ledgerwood, Levi G; Kumar, Dhruv; Eterovic, Agda Karina et al. (2016) The degree of intratumor mutational heterogeneity varies by primary tumor sub-site. Oncotarget 7:27185-98
Reed, Gregory A; Schiller, Gary J; Kambhampati, Suman et al. (2016) A Phase 1 study of intravenous infusions of tigecycline in patients with acute myeloid leukemia. Cancer Med 5:3031-3040
Chen, Fengju; Zhang, Yiqun; ÅženbabaoÄŸlu, Yasin et al. (2016) Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma. Cell Rep 14:2476-89
Parsel, S M; Grandis, J R; Thomas, S M (2016) Nucleic acid targeting: towards personalized therapy for head and neck cancer. Oncogene 35:3217-26
(2016) Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. Nat Commun 7:12675
Mitchell, Julie L; Seng, Amara; Yankee, Thomas M (2016) Expression patterns of Ikaros family members during positive selection and lineage commitment of human thymocytes. Immunology 149:400-412
Hamilton-Reeves, Jill M; Bechtel, Misty D; Hand, Lauren K et al. (2016) Effects of Immunonutrition for Cystectomy on Immune Response and Infection Rates: A Pilot Randomized Controlled Clinical Trial. Eur Urol 69:389-92
Kurahara, Hiroshi; Bohl, Christopher; Natsugoe, Shoji et al. (2016) Suppression of pancreatic cancer growth and metastasis by HMP19 identified through genome-wide shRNA screen. Int J Cancer 139:628-38
Jiang, Yu; Guarino, Peter; Ma, Shuangge et al. (2016) Bayesian accrual prediction for interim review of clinical studies: open source R package and smartphone application. Trials 17:336
(2016) No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecol Oncol 141:386-401

Showing the most recent 10 out of 93 publications